Norepinephrine is a more potent inhibitor of tumor necrosis factor over a range of doses than dopamine

American Surgeon

Volumn 70, Issue 6, 2004, Pages 526-528

  Morgan III, Joe Harris ^a,b   Gamblin, T Clark ^a   Adkins, Jonathan R ^a   Groves, Joshua R ^a   Dalton, Martin L ^a   Ashley, Dennis W ^a  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL CENTER OF CENTRAL GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; LIPOPOLYSACCHARIDE; NORADRENALIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DOSE RESPONSE; HUMAN; SAPHENOUS VEIN; SECRETION;

DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIPOPOLYSACCHARIDES; NOREPINEPHRINE; SAPHENOUS VEIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3142676674     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock. Chest 1993;103:1826-1831 (Pubitemid 23174321)
2. Hannemann L, Reinhart K, Grenzer O, et al. Comparison of dopamine to dobutamine and norepinephrine for oxygen delivery and uptake in septic shock. Crit Car Med 1995;23:1962-1970 (Pubitemid 26002764)
3. Higuchi Y, Hijiya N, Matsuura K, et al. Mouse soluble CD14 truncated at amino acid 71 in transgenic mice: Preventive effect on endotoxin-mediated toxic shock. Pathobiology 2002-2003;70:103-114 (Pubitemid 36002570)
4. Newman WH, Zhang L, Leeper-Woodford SK, Castresana MR. Human blood vessels release tumor necrosis factor-α from a smooth muscle cell source. Crit Care Med 1996;24:294-297 (Pubitemid 26065339)
5. Hardman JG, Limbird LE, Molinoff PB, et al. The Pharmacological Basis of Therapeutics, Ninth ed. New York: McGraw-Hill; 1996.